Biogen’s pivot finally has real products
- Biogen is moving away from a shrinking MS base and toward Alzheimer’s, rare disease, immunology, and eye disease products.
- Q1 2026 revenue was $2.5 billion, up 2% year over year, with growth products reaching $851 million.
- The Apellis deal closed in May 2026, adding SYFOVRE and EMPAVELI after a $5.6 billion purchase.
- LEQEMBI IQLIK was approved for at-home starting doses in July 2026, which could lower a key adoption barrier.
- The bear case is simple: old MS drugs keep fading, new launches must work, and the Apellis debt has to pay off.
A turnaround with proof, not safety
Biogen used to be mostly an MS drug company. That old base is still large, but it is shrinking as TECFIDERA faces generics and TYSABRI faces biosimilar competition. The key change is that the newer products are now big enough to matter. In Q1 2026, Biogen said growth products reached $851 million and topped the remaining legacy MS products for the first time.
The bull case got stronger after Biogen closed the Apellis acquisition in May 2026. The deal adds SYFOVRE for geographic atrophy, an eye disease that can lead to vision loss, and EMPAVELI for rare immune diseases. It also gives Biogen more near-term sales, rather than asking investors to wait years for pipeline trials.
LEQEMBI also moved forward. In July 2026, the FDA approved LEQEMBI IQLIK for at-home starting doses. That matters because the older IV version needs infusion center time, which can slow patient starts. Easier use does not guarantee fast adoption, but it attacks one of the biggest barriers.
The bear case is still real. Biogen paid about $5.6 billion for Apellis and planned to use about $2.0 billion of bank loans. SYFOVRE competes in a market where promotion and doctor confidence matter. Biogen now has a better growth path, but it still has to prove that the new portfolio can outrun the old decline.
Replacing MS cash with launches
Biogen makes money by selling prescription drugs, earning collaboration revenue, and collecting royalties. In Q1 2026, total revenue was $2.48 billion. Product revenue was the biggest piece at $1.75 billion, or 70.7% of revenue.
The old engine is MS. TYSABRI, TECFIDERA, AVONEX, PLEGRIDY, and VUMERITY still bring in large sales, but most of that group is under pressure. TECFIDERA revenue fell 46.9% year over year in Q1 2026 because of generic competition. VUMERITY is the exception, with Q1 2026 revenue up 29.0% to $179.0 million.
The new model is launch-heavy. Biogen is pushing LEQEMBI, SKYCLARYS, ZURZUVAE, QALSODY, high-dose SPINRAZA, and now Apellis medicines. This takes sales spending, doctor education, patient support, and payer coverage. Biogen is using its Fit for Growth cost cuts to help fund that shift.
Where it breaks is simple. If LEQEMBI starts stay slow, SYFOVRE loses share, or SPINRAZA keeps losing patients to oral and gene therapies, the company could be stuck between a fading legacy business and an expensive growth plan.
The drugs that decide the story
Legacy MS franchise
TECFIDERA, TYSABRI, AVONEX, and PLEGRIDY still matter, but the group is under pressure from generics, biosimilars, and patient shifts to newer options.
VUMERITY
Biogen now counts VUMERITY as a growth product. It grew 29.0% year over year to $179.0 million in Q1 2026, making it the bright spot inside MS.
LEQEMBI
LEQEMBI is Biogen’s Alzheimer’s partnership with Eisai. The July 2026 approval of LEQEMBI IQLIK for at-home starting doses could make treatment easier for doctors and patients.
SPINRAZA
SPINRAZA treats spinal muscular atrophy. The high-dose regimen was approved in the U.S., E.U., and Japan, which helps Biogen defend the franchise against oral and gene therapy rivals.
SKYCLARYS, QALSODY, and ZURZUVAE
These newer launches cover Friedreich’s ataxia, SOD1-ALS, and postpartum depression. In Q1 2026, SKYCLARYS reached $150.7 million, QALSODY reached $32.5 million, and ZURZUVAE reached $55.4 million.
SYFOVRE and EMPAVELI
Biogen gained these drugs through Apellis. SYFOVRE gives it a large eye disease market, while EMPAVELI adds rare immune disease revenue.
Late-stage pipeline
Key pipeline bets include BIIB080 for Alzheimer’s tau biology, litifilimab for lupus, felzartamab for kidney and transplant-related immune disease, and zorevunersen for Dravet syndrome.
Q1 revenue mix before Apellis
The mix uses Biogen’s Q1 2026 revenue disclosure. Product revenue includes MS, rare disease, biosimilars, and other medicines, so the Apellis products will change this mix after consolidation.
What could still go wrong
Apellis integration and SYFOVRE pressure
High impact · Medium oddsBiogen paid about $5.6 billion for Apellis and planned to fund part of it with about $2.0 billion in bank loans. SYFOVRE sells into geographic atrophy, a market where rivals, doctor confidence, and sales effort can shift share. If Biogen cannot stabilize or grow SYFOVRE, the deal may add debt without enough earnings power.
LEQEMBI adoption stays slow
High impact · Medium oddsLEQEMBI has a huge possible market, but uptake has been slowed by health system limits such as diagnosis, monitoring, and treatment setup. At-home LEQEMBI IQLIK starting doses help with convenience, but patients still need screening and coverage. If doctors and payers move slowly, Alzheimer’s revenue may not ramp fast enough.
Legacy MS decline outruns launches
High impact · High oddsBiogen’s MS base is still large. TECFIDERA revenue fell 46.9% year over year in Q1 2026, and TYSABRI faces biosimilar competition. VUMERITY is growing, but it may not fully offset pressure across the older MS portfolio.
SPINRAZA loses more SMA patients
Medium impact · Medium oddsSPINRAZA faces oral and gene therapy competitors in spinal muscular atrophy. The high-dose approval gives Biogen a stronger defense and may bring some patients back, but the market remains competitive. A weaker SPINRAZA base would hurt rare disease durability.
Pipeline data disappoints
Medium impact · Medium oddsBiogen’s long-term upside still depends on hard science. BIIB080 must show that lowering tau, a brain protein tied to Alzheimer’s disease, can help cognition. Litifilimab and felzartamab also need strong late-stage data to support the next wave of growth.
Drug pricing and policy pressure
Medium impact · Medium oddsThe IRA Medicare Part D redesign had about a $90 million unfavorable impact on Biogen’s 2025 revenue, focused on SKYCLARYS and MS products. More pricing pressure, Medicare changes, or tariff shifts could weigh on sales and margins. This matters more as Biogen pushes newer high-value drugs.
In one breath
What is Biogen best known for?
Biogen is best known for neurology drugs, especially MS treatments and SPINRAZA for spinal muscular atrophy. It is now trying to become a broader company built around Alzheimer’s, rare disease, immunology, and eye disease drugs.
Why did Biogen buy Apellis?
Biogen bought Apellis to add two marketed drugs right away: SYFOVRE and EMPAVELI. The deal is meant to make revenue growth less dependent on slow pipeline progress.
Why does LEQEMBI IQLIK matter?
LEQEMBI IQLIK lets patients start Alzheimer’s treatment with at-home weekly injections instead of starting with IV infusions. That could lower the burden on patients, doctors, and infusion centers.
Is Biogen already growing again?
Biogen’s Q1 2026 total revenue rose 1.9% year over year, and growth products passed the remaining legacy MS products. That is real progress, but the company still has to offset falling older MS drugs and prove the Apellis deal pays off.